Guillain-Barré syndrome laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include: Elevated CSF protein level, normal CSF WBC count, normal CSF cell count (in some cases there is mildly elevated cell count) and serum IgG antibody to GQ1b in Miller Fisher syndrome.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include:^[1]^[2]^[3]^[4]^[5]
- Elevated CSF protein level.
- Normal CSF WBC count.
- Normal CSF cell count (in some cases there is mildly elevated cell count)
- Serum IgG antibody to GQ1b in Miller Fisher syndrome.

References

↑ Al-Hakem H, Doets AY, Stino AM, Zivkovic SA, Andersen H, Willison HJ; et al. (2023). “CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome”. Neurology. 100 (23): e2386–e2397. doi:10.1212/WNL.0000000000207282. PMID 37076309 Check |pmid= value (help).
↑ Yuki N, Hartung HP (June 2012). “Guillain-Barré syndrome”. N. Engl. J. Med. 366 (24): 2294–304. doi:10.1056/NEJMra1114525. PMID 22694000.
↑ Nishimoto Y, Odaka M, Hirata K, Yuki N (March 2004). “Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination”. J. Neuroimmunol. 148 (1–2): 200–5. doi:10.1016/j.jneuroim.2003.11.017. PMID 14975602.
↑ Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (January 2014). “Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria”. Brain. 137 (Pt 1): 33–43. doi:10.1093/brain/awt285. PMID 24163275.
↑ Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). “Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies”. Neurology. 43 (10): 1911–7. PMID 8413947.

Template:WH Template:WS

[pmid37076309-1] Al-Hakem H, Doets AY, Stino AM, Zivkovic SA, Andersen H, Willison HJ; et al. (2023). “CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome”. Neurology. 100 (23): e2386–e2397. doi:10.1212/WNL.0000000000207282. PMID 37076309 Check |pmid= value (help).

[pmid22694000-2] Yuki N, Hartung HP (June 2012). “Guillain-Barré syndrome”. N. Engl. J. Med. 366 (24): 2294–304. doi:10.1056/NEJMra1114525. PMID 22694000.

[pmid14975602-3] Nishimoto Y, Odaka M, Hirata K, Yuki N (March 2004). “Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination”. J. Neuroimmunol. 148 (1–2): 200–5. doi:10.1016/j.jneuroim.2003.11.017. PMID 14975602.

[pmid24163275-4] Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (January 2014). “Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria”. Brain. 137 (Pt 1): 33–43. doi:10.1093/brain/awt285. PMID 24163275.

[pmid8413947-5] Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). “Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies”. Neurology. 43 (10): 1911–7. PMID 8413947.

[1]

[2]

[3]

[4]

[5]

Guillain-Barré syndrome laboratory tests

Overview

Laboratory Findings

References

Looking for the patient version?